Cingulate to Present at H.C. Wainwright Global Investment Conference
18. Mai 2022 17:20 ET
|
Cingulate Inc.
KANSAS CITY, Kan., May 18, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate Inc. Reports First Quarter 2022 Results and Provides Clinical and Business Update
12. Mai 2022 16:15 ET
|
Cingulate Inc.
KANSAS CITY, Kan., May 12, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate Presents at NobleCon18
26. April 2022 12:27 ET
|
Cingulate Inc.
KANSAS CITY, Kan., April 26, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug...
Cingulate Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Clinical and Business Update
10. März 2022 06:45 ET
|
Cingulate Inc.
Completed Initial Public Offering, Raising Gross Proceeds of $25.0 Million Expedited Clinical Program for CTx-1301 Expected to Reduce Capital Requirements and Time to Approval KANSAS CITY, Kan.,...
Cingulate to Present at Aegis Virtual Conference
15. Februar 2022 06:45 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit/Hyperactivity Disorder (ADHD)
08. Februar 2022 06:45 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate Appoints Curt Medeiros and Gregg Givens to Board of Directors
25. Januar 2022 06:45 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Following its initial public offering last month, Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its...
Cingulate Inc. Announces Closing of Initial Public Offering
10. Dezember 2021 11:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Cingulate Inc. (“Cingulate” or the “Company”), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™...
Cingulate Inc. Announces Pricing of $25.0 Million Initial Public Offering
07. Dezember 2021 21:05 ET
|
Cingulate Therapeutics LLC
KANSAS CITY, Kan., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Cingulate Inc. (“Cingulate” or the “Company”), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™...